IDH1 and glioma: Moreover, patient-derived IDH-mut glioma tumor spheres overexpressing DLL3 were potently and selectively sensitive to anti-DLL3 antibody rovalpituzumab tesirine (Rova-T) in an antigen-dependent manner [64].